SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Gelteq Ltd
Date: July 8, 2025 · CIK: 0001920092 · Accession: 0000000000-25-007162

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288442

Date
July 8, 2025
Author
Division of
Form
UPLOAD
Company
Gelteq Ltd

Letter

Re: Gelteq Limited Registration Statement on Form F-1 Filed July 1, 2025 File No. 333-288442 Dear Nathan Givoni:

July 8, 2025

Nathan Givoni Chief Executive Officer and Director Gelteq Limited Level 4 100 Albert Road South Melbourne VIC, 3025 Australia

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Richard Anslow, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 8, 2025

Nathan Givoni
Chief Executive Officer and Director
Gelteq Limited
Level 4
100 Albert Road
South Melbourne VIC, 3025
Australia

 Re: Gelteq Limited
 Registration Statement on Form F-1
 Filed July 1, 2025
 File No. 333-288442
Dear Nathan Givoni:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Richard Anslow, Esq.
</TEXT>
</DOCUMENT>